Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Stinchcombe, 2008, Considerations for second-line therapy of non-small cell lung cancer, Oncologist, 13, 28, 10.1634/theoncologist.13-S1-28

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643

Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7

Zou, 2008, Inhibitory B7-family molecules in the tumour microenvironment, Nat Rev Immunol, 8, 467, 10.1038/nri2326

Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012

Kim, 2016, Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure), Ann Oncol, 27, 1492, 10.1093/annonc/mdw217

Chen, 2012, Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1, Clin Cancer Res, 18, 6580, 10.1158/1078-0432.CCR-12-1362

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904

Butte, 2007, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, 27, 111, 10.1016/j.immuni.2007.05.016

Yang, 2011, The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo, J Immunol, 187, 1113, 10.4049/jimmunol.1100056

Paterson, 2011, The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo, J Immunol, 187, 1097, 10.4049/jimmunol.1003496

Park, 2010, B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance, Blood, 116, 1291, 10.1182/blood-2010-01-265975

Matsumoto, 2008, B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma, Biochem Biophys Res Commun, 365, 170, 10.1016/j.bbrc.2007.10.156

Akbari, 2010, PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions, Mucosal Immunol, 3, 81, 10.1038/mi.2009.112

Horn, 2015, Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study, J Clin Oncol, 33, 8029, 10.1200/jco.2015.33.15_suppl.8029

Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0

Smith, 2016, Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR), J Clin Oncol, 34, 9028, 10.1200/JCO.2016.34.15_suppl.9028

Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624

Gandara, 2016, Postprogression prolongation of survival in EGFR-mutated lung cancer: reconciling the ASPIRATION and IMPRESS trials, JAMA Oncol, 2, 300, 10.1001/jamaoncol.2015.4920